Subscribe to RSS
Download PDF
DOI: 10.1055/a-1497-1562
Use of stents in patients undergoing chemotherapy for borderline resectable pancreatic cancer-causing biliary obstruction while awaiting surgery: A cost-effectiveness analysis
Abstract
Background and study aims Biliary stenting is indicated to relieve obstruction from borderline resectable pancreatic cancer while patients receive preoperative neoadjuvant therapy. We compared the cost-effectiveness of plastic versus metal biliary stenting in this setting.
Methods A decision tree analysis compares two competing types of biliary stents (initially metal vs. initially plastic) to treat malignant distal biliary obstruction while receiving neoadjuvant therapy with different scenarios including possible complications as bridge till the patient undergoes curative surgical attempt. Using published information, effectiveness was chosen as the probability of successfully reaching a state of being ready for surgery once chemotherapy was completed. Costs (2018 US$) were based on national data. A third-party payer perspective was adopted, and sensitivity analyses were performed over a time-horizon of one year.
Results Initially inserting a metal versus a plastic biliary stent was more efficacious with a higher probability of reaching the readiness for surgery endpoint (96 % vs. 85 %), on average 18 days earlier while also being less expensive (US$ 9,304 vs. US$ 11,538). Sensitivity analyses confirmed robustness of these results across varying probability assumptions of plausible ranges and remained a dominant strategy even when lowering the willingness-to-pay threshold to US$ 1,000.
Conclusions Initial metal stenting to relieve malignant biliary obstruction from borderline resectable pancreatic cancer in patients undergoing neoadjuvant therapy prior to surgery is a dominant intervention in economic terms, when compared to initially inserting a plastic biliary stent as it results in a greater proportion of patients being fit for surgery earlier and at a lower cost.
Publication History
Received: 25 November 2020
Accepted: 20 April 2021
Article published online:
23 August 2021
© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2019; 4: 934-947
- 2 Howlader N, Noone AM, Krapcho M. et al. SEER Cancer Statistics Review, 1975–2016, National Cancer Institute. Bethesda, MD: https://seer.cancer.gov/csr/1975_2016/ [based on November 2018 SEER data submission, posted to the SEER web site, April 2019]
- 3 National Comprehensive Cancer Network. Pancreatic Adenocarcinoma (Version 1.2020). 2020 https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
- 4 Almadi MA, Barkun AN, Martel M. No benefit of covered vs uncovered self-expandable metal stents in patients with malignant distal biliary obstruction: a meta-analysis. Clin Gastroenterol Hepat 2013; 11: 27-37
- 5 Sawas T, Al Halabi S, Parsi MA. et al. Self-expandable metal stents versus plastic stents for malignant biliary obstruction: a meta-analysis. Gastrointest Endosc 2015; 82: 256-267
- 6 Barkun AN, Adam V, Martel M. et al. Partially covered self-expandable metal stents versus polyethylene stents for malignant biliary obstruction: a cost-effectiveness analysis. Canadian J Gastroenterol Hepatol 2015; 29: 377-383
- 7 Kahaleh M, Brock A, Conaway MR. et al. Covered self-expandable metal stents in pancreatic malignancy regardless of resectability: a new concept validated by a decision analysis. Endoscopy 2007; 39: 319-324
- 8 Martinez JM, Anene A, Bentley TG. et al. Cost effectiveness of metal stents in relieving obstructive jaundice in patients with pancreatic cancer. J Gastrointest Cancer 2017; 48: 58-65
- 9 Heinrich S, Besselink M, Moehler M. et al. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study. BMC Cancer 2019; 19: 675
- 10 Mokdad AA, Minter RM, Zhu H. et al. Neoadjuvant therapy followed by resection wersus upfront resection for resectable pancreatic cancer: A propensity score matched analysis. J Clin Oncol 2017; 35: 515-522
- 11 Perez K, Clancy TE, Mancias JD. et al. When, what, and why of perioperative treatment of potentially curable pancreatic adenocarcinoma. J Clin Oncol 2017; 35: 485-489
- 12 Tsuboi T, Sasaki T, Serikawa M. et al. Preoperative biliary drainage in cases of borderline resectable pancreatic cancer treated with neoadjuvant chemotherapy and surgery. Gastroenterol Res Pract 2016; 2016: 7968201
- 13 Kubota K, Sato T, Watanabe S. et al. Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer. Digest Endosc 2014; 26: 77-86
- 14 Heneghan R, Rose J, Alseidi A. et al. A comparative analysis of plastic versus metal endoscopic biliary stents in borderline resectable pancreatic cancer patients undergoing extended neoadjuvant chemotherapy. Gastroenterology 2013; 144: S1129
- 15 Adams MA, Anderson MA, Myles JD. et al. Self-expanding metal stents (SEMS) provide superior outcomes compared to plastic stents for pancreatic cancer patients undergoing neoadjuvant therapy. J Gastrointest Oncol 2012; 3: 309-313
- 16 Nakamura K, Sho M, Akahori T. et al. A comparison between plastic and metallic biliary stent placement in patients receiving preoperative neoadjuvant chemoradiotherapy for resectable pancreatic cancer. World J Surgery 2019; 43: 642-648
- 17 Gardner TB, Spangler CC, Byanova KL. et al. Cost-effectiveness and clinical efficacy of biliary stents in patients undergoing neoadjuvant therapy for pancreatic adenocarcinoma in a randomized controlled trial. Gastrointest Endosc 2016; 84: 460-466
- 18 Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol 2016; 22: 9694-9705
- 19 Barkun AN, Adam V, Lu Y. et al. Using hemospray improves the cost-effectiveness ratio in the management of upper gastrointestinal nonvariceal bleeding. J Clin Gastroenterol 2018; 52: 36-44
- 20 Barkun AN, Adam V, Martel M. et al. Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists. Value Health 2013; 16: 14-22
- 21 Chen YI, Barkun AN, Adam V. et al. Cost-effectiveness analysis comparing lumen-apposing metal stents with plastic stents in the management of pancreatic walled-off necrosis. Gastrointest Endosc 2018; 88: 267-276
- 22 Karim S, Zhang-Salomans J, Biagi JJ. et al. Uptake and effectiveness of FOLFIRINOX for advanced pancreatic cancer: a population-based study. Clin Oncol (R Coll Radiol) 2018; 30: e16-e21
- 23 Neumann PJ, Sanders GD, Russel LB. et al. Cost-effectiveness in health and medicine. 2nd ed. New York, NY: Oxford University Press; 2017
- 24 Almadi MA, Barkun A, Martel M. Plastic vs. Self-expandable metal stents for palliation in malignant biliary obstruction: a series of meta-analyses. Am J Gastroenterol 2017; 112: 260-273
- 25 Almadi MA, Barkun JS, Barkun AN. Stenting in malignant biliary obstruction. Gastrointest Endosc Clin North Am 2015; 25: 691-711
- 26 Crippa S, Cirocchi R, Partelli S. et al. Systematic review and meta-analysis of metal versus plastic stents for preoperative biliary drainage in resectable periampullary or pancreatic head tumors. Europ J Surg Oncol 2016; 42: 1278-1285
- 27 Liu P, Lin H, Chen Y. et al. Comparison of metal and plastic stents for preoperative biliary drainage in resectable and borderline resectable periampullary cancer: a meta-analysis and system review. J Laparoendosc Adv Surg Techniq 2018; 28: 1074-1082
- 28 Walter D, van Boeckel PG, Groenen MJ. et al. Cost efficacy of metal stents for palliation of extrahepatic bile duct obstruction in a randomized controlled trial. Gastroenterology 2015; 149: 130-138
- 29 Dumonceau JM, Tringali A, Papanikolaou IS. et al. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline – Updated October 2017. Endoscopy 2018; 50: 910-930
- 30 Nakai Y, Isayama H, Wang HP. et al. International consensus statements for endoscopic management of distal biliary stricture. J Gastroenterol Hepatol 2020; 35: 967-979
- 31 Eloubeidi MA, Decker GA. ASGE Standards of Practice Committee. et al. The role of endoscopy in the evaluation and management of patients with solid pancreatic neoplasia. Gastrointest Endosc 2016; 83: 17-28
- 32 Kulkarni NM, Soloff EV, Tolat PP. et al. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease. Abdominal Radiol 2020; 45: 716-728
- 33 Pan L, Fang J, Tong C. et al. Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis. World J Surg Oncol 2019; 18: 1-13
- 34 Nennstiel S, Tschurtschenthaler I, Neu B. et al. Management of occluded self-expanding biliary metal stents in malignant biliary disease. Hepatobil Pancreat Dis Int 2018; 17: 49-54
- 35 Woods B, Revill P, Sculpher M. et al. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health 2016; 19: 929-935